Literature DB >> 28321136

Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors.

Dominic A Solimando, J Aubrey Waddell.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.

Entities:  

Year:  2017        PMID: 28321136      PMCID: PMC5345921          DOI: 10.1310/hpj5202-98

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  46 in total

Review 1.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

2.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.

Authors: 
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

3.  Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors.

Authors:  P H Gutin; C B Wilson; A R Kumar; E B Boldrey; V Levin; M Powell; K J Enot
Journal:  Cancer       Date:  1975-05       Impact factor: 6.860

4.  Concurrent modified PCV chemotherapy and radiotherapy in newly diagnosed grade IV astrocytoma.

Authors:  Colleen Murphy; Tom Pickles; Margaret Knowling; Brian Thiesse
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

5.  The treatment of anaplastic oligodendrogliomas and mixed gliomas.

Authors:  A P Kyritsis; W K Yung; J Bruner; M J Gleason; V A Levin
Journal:  Neurosurgery       Date:  1993-03       Impact factor: 4.654

6.  Low-grade oligodendroglioma responds to chemotherapy.

Authors:  W P Mason; G S Krol; L M DeAngelis
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

Review 7.  Hepatotoxicity of chemotherapy.

Authors:  Justin Floyd; Irfan Mirza; Bradley Sachs; Michael C Perry
Journal:  Semin Oncol       Date:  2006-02       Impact factor: 4.929

8.  Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.

Authors:  Jan C Buckner; Dean Gesme; Judith R O'Fallon; Julie E Hammack; Scott Stafford; Paul D Brown; Roland Hawkins; Bernd W Scheithauer; Bradley J Erickson; Ralph Levitt; Edward G Shaw; Robert Jenkins
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

9.  Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.

Authors:  Edward G Shaw; Meihua Wang; Stephen W Coons; David G Brachman; Jan C Buckner; Keith J Stelzer; Geoffrey R Barger; Paul D Brown; Mark R Gilbert; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Pre-radiation chemotherapy for malignant glioma in adults.

Authors:  S Kirby; D Macdonald; B Fisher; L Gaspar; G Cairncross
Journal:  Can J Neurol Sci       Date:  1996-05       Impact factor: 2.104

View more
  1 in total

Review 1.  Therapeutic Options in Neuro-Oncology.

Authors:  Mariana Afonso; Maria Alexandra Brito
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.